Zynerba Pharmaceuticals — Investor Presentation (September 2019)
39 slides from Zynerba Pharmaceuticals's investor presentation, Sep 24, 2019
Slide 1: Forward-Looking Statements
Forward-Looking Statements 2 © 2019 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STA
Slide 2: A Rare/Near-Rare Neuropsychiatric Company
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near-Rare Neuropsychiatric Company Deep pipeline focused on high unmet medical needs; translating into multi-billion dollar market opportunity with Zygel™(CBD transdermal gel) Four clinical shots on goal: FXS, DEE, ASD, 22q Reported compelling safety a
Slide 3: Deep Clinical Pipeline
Deep Clinical Pipeline 4 *Orphan Drug Designation Zygel Cannabidiol Gel
Slide 4: Zygel (ZYN002) Cannabidiol Gel
Neuropsych Indications Differentiated Formulation delivers CBD through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol (CBD) Gel 5 Unique MOA First & only patent-protected, permeation-enhanced, pharmaceutically- produced CBD gel Transdermal CBD modulates multiple receptors a
Slide 5: DEE: Developmental and Epileptic Encephalopathies
DEE Developmental and Epileptic Encephalopathies 6
Slide 6: BELIEVE 1 Phase 2 Trial in DEE
BELIEVE 1 Phase 2 Trial in DEE 7 Open LaBel Study to Assess the Safety and Efficacy of ZYN002 Administered as a TransdermaL Gel to ChIldren and AdolEscents with DeVelopmental and Epileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Titration 4 We
Slide 7: Compelling Results from the BELIEVE 1 Trial Appear to have been Misinterpreted
8 DEE is a medically fragile population and adverse events are common and expected Safety results: Zygel was well tolerated Consistent with previously reported Zygel studies Compare favorably to previously reported oral CBD solution data Zynerba approach to FDA approval will likely focus on most com
Slide 8: DEE Patients are Medically Fragile
DEE Patients are Medically Fragile 9 Group of rare / ultra rare childhood-onset epilepsies with impaired or regressed developmental progress Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic Medically fragile population Comorbidities include cerebral palsy, chron
Slide 9: BELIEVE 1 Safety: Well Tolerated over 6 Month Trial
10 DEE is a fragile population; adverse events (AEs) common and expected 96% of patients experienced an AE All events whether unrelated or related to study drug were reported as AEs (e.g.: influenza, runny nose, ingrown toenail, scrapes, etc.) Most were mild and transient Only one patient discontinu
Slide 10: Planned Approach to FDA – All DEE Patients with Consciousness Impairing Seizures
11 Planned Approach to FDA – All DEE Patients with Consciousness Impairing Seizures Syndromes and encephalopathies Dravet LGS West Early myoclonioc epilepsy Hypoxic-ischemic enceph. Seizure type Focal Impaired Awareness Bilateral Tonic Clonic Generalized Tonic Clonic Focal aware Absence Convulsive O
Slide 11: BELIEVE Patient Disposition
BELIEVE 1 Patient Disposition 12 Enrolled 48 DEE patients 46 patients included in the mITT population Two patients excluded: One < 80% of daily seizure diary completion One < 80 days of treatment 33 patients included in efficacy analysis 13 excluded No FIAS or convulsive seizures All 48 patients inc
Slide 12: Oral CBD Solution Open Label Patient Disposition
13 214 patients enrolled 52 enrolled but did not have 12 weeks of follow up after first dose of cannabidiol 11 stopped treatment before 12 weeks 1 sesame allergy 1 hepatoxic event 1 excessive somnolence and poor efficacy 1 gastrointestinal intolerance 4 worsening seizures and poor efficacy 1 hyperam
Slide 13: BELIEVE 1: Clinically Meaningful Seizure Reductions Sustained through Six Months
14 BELIEVE 1: Clinically Meaningful Seizure Reductions from Baseline and Sustained through Six Months in DEE N=33 N=33 N=33 N=32 N=32 N=29 16 44 44 47 58 51 N=33 N=33 N=33 N=32 N=32 N=29 30 42 46 47 63 55 Median Percent Reduction % of Pts with 50% Median Seizure Reduction % % % % % % % % % % % % % %
Slide 14: BELIEVE 1: Qualitative Assessments of Behavioral and Cognitive Improvements
15 Parents and caregivers provided qualitative assessment on their child’s overall experiences with Zygel Improvements were seen in seizure intensity and duration, and socio-behavioral and cognitive impairments Findings: 58% reported improved vitality (e.g. alertness / awareness, energy) 51% reporte
Slide 15: Compelling Results Suggest a Pathway to Pivotal Trials
16 DEE is a medically fragile population and adverse events are common and expected Safety results: Zygel was well tolerated Consistent with previously reported Zygel studies Compare favorably to previously reported oral CBD solution data Zynerba approach to FDA approval will likely focus on most co
Slide 16: Compelling Results Suggest a Pathway to Pivotal Trials — Anticipate Meeting with FDA in 1H2020
Compelling Results Suggest a Pathway to \ Pivotal Trials — Anticipate Meeting with FDA in 1H2020 - DEE is a medically fragile population and adverse events are common and expected + Safety results: +» Zygel was well tolerated + Consistent with previously reported Zygel studies » Compare favorably to
Slide 17: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 18 Rare genetic developmental disability Leading known cause of both inherited intellectual disability and autism spectrum disorder Symptoms linked to deficiencies in the endocannabinoid (EC) system System of neurotransmitters regulating emotional responses, behavio
Slide 18: Recent Development Progress in FXS
Recent Development Progress in FXS 19 Presented new data at SSBP (September 2019) Data further validate the ABC-CFXS to assess core behaviors of FXS ASD, FXS and 22q share a constellation of socio-behavioral symptoms Recently issued US patent directed to methods of treating FXS with cannabidiol exte
Slide 19: FAB-C Open Label Phase 2 Trial Design
Day 1 to Week 6 Week 7 to 12 Up to 24 months FAB-C Open Label Phase 2 Trial Design 20 Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD Titration Maintenance Screening Open label extension Dosing initiated at 50 mg Zygel daily; may be titrated up to 250 mg Zygel daily Doses
Slide 20: FAB-C Month Three: Percent Improvement in Behavioral Symptoms of FXS
FAB-C Open Label Phase 2 21 Baseline: 18.2 Baseline: 14.5 Baseline: 8.7 Baseline: 5.1 Baseline: 7.9 Baseline: 6.1 41.8% 52.9% 54.9% 32.4% 59.5% 42.6% P=0.0005 P=0.0096 P=0.0034 P=0.0018 P=0.0006 P=0.0237 Mean % Improvement from Baseline Month Three: ABC-CFXS Mean Score Percent Improvement in Behavio
Slide 21: FAB-C ABC-CFXS Subscales Month Three vs. 3rd Party Data
FAB-C ABC-CFXS Subscales 22 Month Three: Percent Improvement vs. 3rd Party Data* Socially Unresponsive / Lethargic Does not pay attention Inappropriate Speech Repeats words / phrases Stereotypy Repetitive movements Hyperactivity Disrupts group activities Social Avoidance Seeks isolation Irritability
Slide 22: FAB-C Month 3 and 12: Percent Improvement in Behavioral Symptoms of FXS
FAB-C Open Label Phase 2 23 Month 3 and 12: ABC-CFXS Mean Score 57.9* 51.1* 65.7* 36.7* 60.8* 56.5* *P 0.05 Percent Improvement in Behavioral Symptoms of FXS Mean % Improvement from Baseline 77.2* 59.2* 72.2* 40.4* 64.9* 56.5* Patients Completing 12 Months Data from American Psychiatric Association
Slide 23: Zygel Safety Summary Through 12 Months
FAB-C Open Label Phase 2 24 Well tolerated, consistent with previously reported data; no SAEs No clinically meaningful trends in vital signs, ECG, or clinical safety labs including LFTs; no THC detected in plasma Discontinuations Two siblings discontinued in Period 1 One for worsening of pre-existin
Slide 24: CONNECT-FX: A Pivotal Trial In FXS
CONNECT-FX: A Pivotal Trial In FXS 25 Clinical study Of CaNNabidiol (CBD) in ChildrEn and AdolesCenTs with Fragile X (CONNECT-FX) Zygel 250 mg daily 500 mg daily (weight-based dose) Placebo Mirrors Zygel administration Patients randomized (1:1) to receive either Zygel or placebo Treatment Target: 20
Slide 25: CONNECT-FX: A Pivotal Trial In FXS – Endpoints
CONNECT-FX: A Pivotal Trial In FXS 26 Primary endpoint: Change from baseline to end of treatment in ABC-CFXS Social Avoidance subscale Key secondary endpoints: Change from baseline to end of the treatment in ABC-CFXS Irritability subscale score ABC-CFXS Socially Unresponsive/Lethargic subscale score
Slide 26: CONNECT-FX: Planned FDA Meeting
CONNECT-FX 27 With positive results, Zynerba intends to request a meeting with the FDA to: Determine acceptability of data as basis for NDA filing Seek advice on marketing authorization preparation Zynerba believes indication may include the treatment of behavioral symptoms associated with FXS Evalu
Slide 27: Autism Spectrum Disorder (ASD) in pediatric patients
28 Autism Spectrum Disorder (ASD) in pediatric patients
Slide 28: ASD in Pediatrics Overview
ASD in Pediatrics Overview 29 Near-rare disorder affecting <1MM pediatric and adolescent pts DSM-5 diagnosis Includes Autistic disorder, Asperger’s syndrome, and Pervasive Development Disorder-not otherwise specified (PDD-NOS) Symptoms include Anxiety Restricted, repetitive patterns of behavior Impa
Slide 29: Developing Zygel in ASD
Developing Zygel in ASD 30 Newer studies suggest ASD is linked to disruption in the EC system Altered anandamide signaling may contribute to ASD-related social and communication impairments EC system modulates many cellular functions and molecular pathways altered in ASD: imbalanced GABAergic, gluta
Slide 30: BRIGHT Phase 2 Trial in ASD
BRIGHT Phase 2 Trial in ASD 31 Open-LaBel ToleRabIlity and Efficacy Study of ZYN002 Administered as a Transdermal Gel to CHildren and AdolescenTs with Autism Spectrum Disorder Target: 36 patients Four through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks: ONGOING 250 mg to 5
Slide 31: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome (22q) 32
Slide 32: 22q Overview
22q Overview 33 Most common contiguous gene deletion syndrome Rare disorder: ~81K patients in US Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities common a
Slide 33: 22q Patient Management
22q Patient Management 34 Two primary stages of 22q patient management: During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety and auti
Slide 34: Developing Zygel in 22q
Developing Zygel in 22q 35 CBD may treat neuropsychiatric symptoms in 22q due to activity as: Agonist at serotonin 1A receptors Antagonist at GPR55 receptors Modulator of endocannabinoid system Early control of anxiety may delay the development of psychosis Phase 2 study underway in pediatric and ad
Slide 35: INSPIRE Phase 2 Trial in 22q
INSPIRE Phase 2 Trial in 22q 36 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks: ONGOING 250 mg to 500 mg daily Enrollment ongoing Follow up assessments Week 16 / 17 Efficacy assessments (week 14 vs baseline) include: Aberrant Behavior Checklist
Slide 36: Financial Strength
Financial Strength 37 Clean balance sheet No debt, 23.2M shares outstanding (as of August 6, 2019) Cash and cash equivalent position of $88.7M as of June 30, 2019 Advance Overseas Finding expected to generate an incremental $7.0 to $9.0 million over the next 18 to 24 months Cash expected to be suffi
Slide 37: Expected Milestones into 2020
Report pivotal CONNECT-FX topline results Expected Milestones into 2020 38 FXS DEE Other indications 1Q 2Q 3Q 4Q 2019 Present/publish additional data from Phase 2 FAB-C study Report pivotal CONNECT-FX topline results ASD Initiate Phase 2 BRIGHT study 22q Initiate Ph2 INSPIRE study Ph 2 data: BELIEVE
Slide 38: Corporate Overview September 2019
Corporate Overview September 2019
Slide 39: Zynerba Pharmaceuticals Corporate Overview
_— Zynerba PHARMACEUTICALS Advancing Science | Improving Connections Corporate Overview September 2019
Zynerba Pharmaceuticals — Investor Presentation (September 2019) on 6ix